Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Bacillus/Trapa japonica fruit ferment filtrate extracts enhanced human hair follicle dermal papilla cell proliferation through the Akt/ERK/GSK-3β signaling pathway, suggesting potential benefits for alopecia treatment.

CTP-543 is generally safe for treating alopecia areata.

This case report describes a 15-year-old girl with features of Becker naevus syndrome, highlighting the importance of DNA analysis from skin to confirm the diagnosis after 9 years of symptoms.

This study explores the hypothesis that preoperative administration of botulinum toxin could enhance hair transplantation outcomes by improving scalp microenvironment and reducing ischemia-induced graft failure, using a randomized split-scalp controlled trial design.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

This study reports that in a rat model of myocardial infarction, Zn-Cu ion sequential therapy improved cardiac function and cardiomyocyte metabolic activity by precisely regulating ion concentrations and maintaining elevated levels of the Per2 protein, important for cellular repair.

This study found that lower expression of Septin4 is significantly associated with worse outcomes in colon cancer, and its interaction with BAX in DOX treatment suggests its potential in targeted therapy.

This case series highlights that anti-TNF agents, though beneficial for autoimmune conditions, can cause a rare adverse reaction of psoriasiform alopecia areata, stressing the importance of specific histopathological features for accurate diagnosis and better management to avoid unnecessary drug discontinuation.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

This study found that both intradermal botulinum toxin A and intradermal minoxidil were equally effective for treating androgenetic alopecia, showing improvement in hair count with advantages like minimal invasiveness and absence of major side effects; minoxidil was also noted to be more cost-effective.

This case report details three patients with follicular mycosis fungoides, highlighting an impressive response to bexarotene in advanced cases, suggesting potential for further research on this treatment's effectiveness.

In this study, photobiomodulation therapy applied twice weekly for 12 weeks significantly improved hair regrowth and quality of life in alopecia areata patients, with no noted side effects.

This study found that the combination of letrozole and quercetin loaded in spanlastics showed enhanced cytotoxicity and other anticancer effects against MCF-7 breast cancer cells compared to individual treatments.

In this report, an 18-year-old female with trichotillomania was successfully treated using the glutamate modulator n-acetylcysteine.

This study outlines a randomized trial to assess if administering botulinum toxin before hair transplantation can improve outcomes by enhancing blood flow and reducing ischemia-induced graft failure in patients with androgenetic alopecia.

This study found that minoxidil and ranolazine, individually and in combination, reduced cellular invasiveness in hypoxic triple-negative breast cancer cell lines, suggesting potential anti-metastatic effects at clinically relevant doses.

HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.

This study found that oral paclitaxel combined with encequidar improved tumor response rates compared to intravenous paclitaxel in women with metastatic breast cancer, while also reducing neuropathy but increasing certain gastrointestinal and neutropenic side effects.

This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.

The study found that cyproterone acetate could be released over 15 days using coconut oil mixed with certain wax inhibitors, though further safety studies are needed.

This study found that the genetic variants rs231775 and rs3087243 of the CTLA4 gene are not associated with alopecia areata in the Mexican population analyzed.

This study found that breast cancer patients treated with the docetaxel-doxorubicin regimen experienced various adverse drug reactions, with nausea being the most common and mainly mild in severity.

This study found that MEGA PROTAC improved the prediction of ternary structures with higher maximum DockQ scores compared to the BOTCP method in 16 out of 22 test cases.

This study reports that a 15-year-old with trichotillomania showed improvement with aripiprazole treatment, though no consensus on treatment exists in the literature.

This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.

This case report highlights a rare instance of severe multi-organ involvement following a single dose of methotrexate for ectopic pregnancy, requiring intensive care but ultimately successfully treated with leucovorin and supportive care.

This study found that group behavior therapy for trichotillomania led to greater short-term symptom improvement compared to supportive therapy, but did not achieve clinically significant changes or prevent relapse over six months.

This article discusses the impact of the tabby mutation on secondary vibrissae and hair follicle patterns in mice and reports no new clinical results.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.